Makoto Tahara
A5011675274- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Thyroid Cancer Diagnosis and Treatment
- Head and Neck Surgical Oncology
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Immunotherapy and Immune Responses
- Brain Metastases and Treatment
- Colorectal and Anal Carcinomas
- Radiopharmaceutical Chemistry and Applications
- Gastric Cancer Management and Outcomes
- Oral health in cancer treatment
- Salivary Gland Tumors Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Esophageal Cancer Research and Treatment
- Ear and Head Tumors
- Plant Virus Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Immune Cell Function and Interaction
- Chromosomal and Genetic Variations
- Glioma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
National Cancer Center Hospital East
2016-2025
Tochigi Medical Center
2023
National Cancer Centre Japan
2018-2023
Kobe University Hospital
2009-2022
Pfizer (United States)
2003-2022
Ono Pharmaceutical (Japan)
2022
Bristol-Myers Squibb (Germany)
2022
Ono Pharmaceutical (United Kingdom)
2022
Chugai Pharma (United States)
2022
Merck Serono (Switzerland)
2022
Patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum chemotherapy have a very poor prognosis limited therapeutic options. Nivolumab, an anti-programmed death 1 (PD-1) monoclonal antibody, was assessed as treatment for this condition.In randomized, open-label, phase 3 trial, we assigned, in 2:1 ratio, 361 patients whose disease had progressed within 6 months platinum-based to receive nivolumab (at dose mg per kilogram body weight) every 2 weeks...
Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast 1 through 4, platelet-derived receptor α, RET, KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).In our randomized, double-blind, multicenter progressive iodine-131, we randomly assigned 261 receive lenvatinib (at daily dose 24 mg per day 28-day cycles) 131 placebo. At the time disease...
Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) the KEYNOTE-012 trial. Results from expansion cohort, which patients HNSCC, irrespective of biomarker status, received a fixed dose pembrolizumab less frequent dosing schedule, are reported. Patients Methods R/M...
Second-line treatment options for advanced head and neck squamous cell carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety efficacy of pembrolizumab HNSCC after long-term follow-up.
Targeting the programmed cell death protein 1 (PD-1)/programmed ligand (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC). Combining immunotherapies targeting PD-L1 cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) shown evidence of additive activity several tumor types. This phase III study evaluated efficacy durvalumab (an anti-PD-L1 monoclonal antibody) or plus tremelimumab anti-CTLA-4 versus standard care (SoC) R/M HNSCC...
Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head neck squamous cell carcinoma KEYNOTE-048. Post hoc analysis of long-term progression-free survival on next-line therapy (PFS2) is presented.
The phase III KEYNOTE-048 (ClinicalTrials.gov identifier: NCT02358031) trial of pembrolizumab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) included planned efficacy analyses the total population participants with programmed death ligand-1 (PD-L1) combined positive score (CPS) ≥ 1 CPS 20. To further characterize predictive value PD-L1 expression on outcome, we conducted < 1-19 subgroups KEYNOTE-048.
Cetuximab, which modulates immune responses, may affect the efficacy of subsequent immunotherapy. Here, we assessed outcomes with nivolumab, by prior cetuximab exposure, in patients recurrent or metastatic (R/M) squamous cell carcinoma head and neck (SCCHN) who had experienced progression within 6 months platinum-containing chemotherapy.In randomized, open-label, phase III CheckMate 141 trial, were randomized 2:1 to nivolumab 3 mg/kg every 2 weeks investigator's choice (IC) single-agent...
PURPOSE The standard treatment for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) is chemoradiotherapy with 3-weekly cisplatin (100 mg/m 2 ). However, whether weekly (40 ) yields comparable efficacy in LA-SCCHN unknown. PATIENTS AND METHODS In this multi-institutional open-label phase II/III trial, patients were randomly assigned to receive either or confirm noninferiority cisplatin. primary end point II was proportion completion, that III...
Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was evaluate the efficacy safety larotrectinib in primary central nervous system (CNS) tumors.Patients CNS tumors from two clinical trials (NCT02637687, NCT02576431) were identified. endpoint investigator-assessed objective response rate (ORR).As July 2020, 33 identified (median age: 8.9 years;...
CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab cisplatin/carboplatin fluorouracil ≤ six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET-mutant medullary thyroid cancer phase 1–2 trial, but its as compared with approved multikinase inhibitors is unclear. Download PDF of the Research Summary. We conducted 3, randomized trial comparing selpercatinib first-line therapy physician's choice cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment. The primary end...
There remains an unmet need to improve clinical outcomes in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
The combination of docetaxel, cisplatin, and 5-fluorouracil (DCF) as preoperative treatment for esophageal squamous cell carcinoma (ESCC) has not been investigated. We carried out a multicenter phase II feasibility study chemotherapy with DCF ESCC. Patients clinical stage II/III ESCC (International Union Against Cancer TNM classification system, 6th edition) were eligible. Chemotherapy consisted i.v. docetaxel (70-75 mg/m(2)) cisplatin on day 1, continuous infusion fluorouracil (750...
Lenvatinib has been approved by regulatory agencies in Japan, the United States, and European Union for treatment of radioiodine-refractory differentiated thyroid cancer (RR-DTC). Thyroid cancer, however, is a clinically diverse disease that includes anaplastic (ATC), subtype associated with highest lethality. Effective therapy ATC an unmet need.This phase 2, single-arm, open-label study patients including ATC, RR-DTC, medullary was conducted from 3 September 2012 to 9 July 2015. Patients...